Product name used for thymosin-β4 or a related fragment

TB-500

Actin · Repair

TB-500 is often equated online with full thymosin-β4, but analytically it can also refer to a shorter fragment. Many wound studies tested full Tβ4; those findings cannot automatically be assigned to every TB-500 product.

2Overview
2× / wkReference frequency
DataPreclinical and limited human Tβ4 research
Research status

Product identity and clinical extrapolation are uncertain

Velora TB-500 vial
TB-5005 MG
01 · Overview

What is TB-500?

TB-500 is often equated online with full thymosin-β4, but analytically it can also refer to a shorter fragment. Many wound studies tested full Tβ4; those findings cannot automatically be assigned to every TB-500 product.

Research route, formulation and population determine what a result actually means.

01

Actin

Thymosin-β4 binds actin and influences cell migration and wound repair.

02

Repair

Studies cell migration, vessel formation and matrix repair in wound models.

02 · Research

What do the studies show?

Preclinical and limited human Tβ4 research. Educational information. Not diagnosis, treatment or use advice.

03 · DATA

Peptide and product specifications

Checked identity data for this research compound or blend.

TB-500Peptide and product specifications
Molecular formula
C₃₈H₆₈N₁₀O₁₄
Molecular weight
889.04 g/mol
CAS number
885340-08-9
Amino-acid sequence / components
Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln
Amino-acid count
7
Purity
Batch-specific - confirm identity and purity with the Velora COA
Reference form
White lyophilised powder
Reference diluent
Formulation- and batch-specific; there is no universal diluent for every research compound
Unreconstituted-material storage
Follow the accompanying COA, product label and validated stability data

These are compound references, not a batch certificate. Purity and identity of a specific Velora batch must be confirmed by its accompanying COA and laboratory report.

04 · Calculator

Reconstitution and U-100 conversion

This module only converts concentration and volume. Inputs are not recommendations or individual dosing advice.

Calculator

Twice weekly in educational protocols

1
2
3
4
Draw to
0 units
0.00 mL
TB-500 vial
TB-500
5 MG
Concentration-
Per unit-
Complete amounts-
Calculated duration-
LAB · RECONSTITUTION

How to reconstitute TB-500 for laboratory research

A visual workflow for controlled laboratory reconstitution. Always follow the product label, COA and a validated protocol.

Five visual laboratory reconstitution steps: clean, measure diluent, add slowly, swirl gently and store according to protocol.
1

Clean

Disinfect the rubber closures of both vials and allow them to dry.

2

Measure diluent

Withdraw only the diluent validated for the specific compound.

3

Add slowly

Let the liquid run slowly down the inside wall of the vial.

4

Swirl gently

Do not shake; rotate gently until the material has dissolved.

5

Store per protocol

Follow the product label, COA and validated stability data.

Important checks before and after reconstitution

Check the product

First confirm that the product is a lyophilised vial. Prefilled pens and ready-to-use solutions do not require reconstitution. Check the label, COA and specified diluent.

Use clean, sterile technique

Wash your hands, clean the work surface and use new sterile equipment for every procedure. Clean both rubber closures with separate alcohol swabs and let them dry completely.

Concentration, not total amount

The volume of liquid added changes the concentration in mg per mL, but not the total amount of research compound in the vial. Use the calculator to check this in advance.

Inspect and label

Check for unexpected discoloration, cloudiness or visible particles. Record the compound, concentration and reconstitution date. Storage time and temperature are product-specific; a fixed 28-day rule does not apply to every compound.

General reconstitution volumes listed by the source

General examples, not a product-specific protocol. The chosen volume determines concentration; always check the label, COA and calculator.

Vial strengthCommonly listed volume
2 mg1–2 mL
5 mg2–3 mL
6 mg2–3 mL
10 mg2–4 mL
15 mg3–5 mL
20 mg4–8 mL

Practical background source: Free Medical Journals - Complete Step-by-Step Guide to Peptide Reconstitution, accessed July 2026. This is a secondary educational source; the product label, COA and validated stability data remain authoritative.

05 · Safety and limitations

Safety and limitations

Research route, formulation and population determine what a result actually means.

What is known

  • Visible research claims use primary or official sources.
  • The calculator is arithmetic and does not turn a study amount into medical advice.
  • A registered medicine and a research vial are not automatically equivalent.

What remains uncertain

  • Many products lack long-term safety data and independent replication.
  • Animal and cell findings do not predict a safe human dose.
  • Stability depends on formulation, pH, sterility, light, temperature and packaging.
Status: Product identity and clinical extrapolation are uncertain. Educational information. Not diagnosis, treatment or use advice.
06 · FAQ

Frequently asked questions

TB-500 is often equated online with full thymosin-β4, but analytically it can also refer to a shorter fragment. Many wound studies tested full Tβ4; those findings cannot automatically be assigned to every TB-500 product.
Full thymosin-β4 accelerated closure and influenced angiogenesis in animal models. Small human wound research with Tβ4 is directional but does not prove systemic tendon or muscle treatment with TB-500.
No. It performs arithmetic conversions only. Medical decisions belong with a licensed healthcare professional.
The curve follows the agreed storage model and is not a laboratory result.
2–8 °C. Protect from light and repeated freeze-thaw cycles.
07 · Sources

Primary research sources

Educational information. Not diagnosis, treatment or use advice.

Thymosin beta4 accelerates wound healing Journal of Investigative Dermatology, 1999. Link
The effect of thymosin treatment of venous ulcers Annals of the New York Academy of Sciences, 2010. Link